Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wibical
- Development stage
- Unknown
- Lead developer
- GP Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Wibical is a formulation of bicalutamide, a non-steroidal antiandrogen, developed and manufactured by GP Pharma. It functions as a small molecule androgen receptor antagonist that competitively inhibits the binding of androgens to their receptors in prostate tissue. By blocking androgen signaling, it prevents the stimulation of prostate cancer cell growth. Wibical is available as film-coated tablets in 50 mg and 150 mg strengths and is primarily indicated for the treatment of advanced or metastatic prostate cancer, typically used in combination with gonadotropin-releasing hormone (GnRH) analogues or surgical castration.
- Brand names
- Wibical
- Other names
- bicalutamide
02
Targets
AR (Adrenergic receptors)
Beyond the preview
Go deeper on Wibical.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wibical.